FDA grants quizartinib priority review for the treatment of relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation

On 21 November 2018, the US Food and Drug Administration (FDA) accepted a New Drug Application (NDA) and granted priority review to quizartinib, an oral, highly potent and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, for the treatment of adult patients with relapsed/refractory (R/R) FLT3-ITD-mutated acute myeloid leukemia (AML). This comes after the FDA granted a Breakthrough Therapy Designation to quizartinib for the treatment of R/R FLT3-ITD AML in August 2018.

The NDA application for quizartinib was based on data from the pivotal phase III randomized QuANTUM-R study, which is assessing the efficacy and safety of quizartinib (60 mg, with a 30 mg lead-in for 15 days) versus salvage chemotherapy (SC) in patients with R/R FLT3-ITD-mutated AML. Data from this study were presented by Jorge Cortes from the MD Anderson Cancer Center, Houston, Texas, at the 23rd Congress of the European Hematology Association, Stockholm, Sweden in June 2018. Single-agent quizartinib significantly prolonged overall survival in patients with R/R FLT3-ITD AML compared to SC. More results from this phase III randomized study are reported here.

Jorge Cortes, in an interview with the AML Global Portal (AGP), highlighted that the QuANTUM-R trial was a “very positive study”, and he hopes that it leads to a “regulatory approval” for quizartinib as it “offers an advantage” over the current treatment options for these difficult to treat patients. The drug manufacturers also added that “quizartinib has the potential to meaningfully advance treatment for patients with relapsed or refractory FLT3-ITD AML” if approved.  

  1. PR Newswire: FDA Grants Priority Review for Daiichi Sankyo's New Drug Application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML. 2018 Nov 21. https://www.prnewswire.com/news-releases/fda-grants-priority-review-for-daiichi-sankyos-new-drug-application-for-flt3-inhibitor-quizartinib-for-treatment-of-patients-with-relapsedrefractory-flt3-itd-aml-300754221.html [Accessed 26 Nov 2018].
  2. Cortes J. et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated (MUT) relapsed/refractory AML in the phase 3, randomized, controlled QuANTUM-R trial. Abstract LB2600. 23rd Congress of the European Hematology Association; 2018 June 14–17, Stockholm, SE.
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!